Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Only good stocks get manipulated like this, because they are the only ones that can rebound after an attack. Bad stocks just dwindle away into nothingness and can't produce the type of volatility the MMs and hedgies crave.
This aggressive attack on NO NEWS tells me that the MMs and hedgies want to scare shares loose in a big way before the GOOD NEWS comes out (in a matter of days/weeks)...then cover and accumulate just prior. If the news is as good as we're anticipating, the PPS will rocket past 6.35 in a heartbeat.
I don't recall that detail being raised or addressed during the meeting...whether there's currently 30 or 32 participating patients.
AMEN! :)
You're all welcome... Glad to be the eyes and ears at the meeting on behalf of all shareholders. GLTL!
Additional tidbit from the shareholders' mtg...
Dr. M did a great job of explaining the mechanism behind the science with regard to the Sigma-1 receptor, in that 2-73 has been proven to be an agonist (helper) to Sigma-1 which is an agonist to cell "health"...not just within the brain, but the entire body. Therefore, they believe that 2-73 might very well be proven, over time, to improve such things as heart health, as well. What an amazing new platform drug we're potentially witnessing.
Regarding potential early approval: It's very possible that 2-73 could be FDA approved for Rett's before Alz. If that happens, then 2-73 might be available sooner...and doctors could write prescriptions off label, for other indications.
Regarding AD P3 trial timing and potential FDA approval... It's been mentioned that the P3 trial will likely begin late this year or early next. Aricept was approved after 6 months into P3 trial.
So, between Rett's approval and Alz approval, you can draw your own conclusions with regard to early timing (potential).
Perhaps... but there is also a possibility that the US media will pick up on the news coming out of Australia and it starts spreading, bringing in many new investors.
We're hoping that they'll have the partnership lined up by the time they release the data... double whammy!
Nothing more than what I posted. The FB group had forwarded a list of 14 questions on Tuesday, which they acknowledged receiving, but they could not respond to them at this time...but will in due time.
That question did not come up. As you can imagine there were a lot of questions being thrown at them and after awhile they cut it off due to time limit. We fully expect a partnership.
Greetings from NYC! Thanks for your patience; I just returned to my hotel room after the shareholders mtg and a nice leisurely lunch with the FB Investors group.
The FB group (~12) made up at least half of the attendees. After the formalities of the meeting and voting were done, Dr. M walked us through the entire updated Corporate presentation adding a bit of color and elaboration in the process. Their attorney was also present (of course) and was providing non-verbal feedback to Dr. M throughout, before he would respond to questions. They were very cautions on what was said.
The attorney made it clear, in a nice way, that they cannot provide any more information today than is public knowledge...and that the regulators occasionally call when they hear things and see various tweets. The attorney is very well aware of the negative marketing and misinformation that is out there and so do the regulators. Their position is not to respond, because it only opens the door for more attacks. And they refuse to even talk to anyone who has ties to SA, MF, etc. That was good to hear.
They did not even hint at when the 12-wk data would be available, but will report when it is. So we can't speculate if it will be via a PR or conference. The group feels that if it's not at the May 17 conference, then it will likely be by or at the June 7 conference.
There was also no discussion about a partnership, though we feel it is in the works.
We all came away feeling very encouraged and uplifted by the tone of the meeting and the company's reaction and engagement with us shareholders.
Not one shareholder in our group plans to sell any of their shares anytime soon. Actually, several plan to add if the price continues to drop.
P.S. They also said that they were not in anyway involved in the press that was released from Australia about the improving patients...as well, it was not done for the benefit of trial recruiting. It was information that was leaked from the trial and the media followed up on it.
We're in pressure cooker mode. When the data and partner news is released, the top will blow!
I saw where short interest rose by 5%. What are they thinking? Perhaps further delay?
Seems most everyone on this board knows I'm RIGHT, except for you. So, do you feel foolish or just called out?
Simple case and point...
AXON: IPO, MC > $1.5B and holding PPS without good news or retail participation (just look how vacant the YMB is)
AVXL: no IPO (hedgies shut out), MC < $200M which goes up on good news, but then is shorted back down by the cartel.
So, try again.
You bet... there will be a group of us, so we'll be able to compare our interpretations before posting.
What Market? "True" markets (or should I say less rigged) only apply to large cap companies where manipulation is impeded by the masses. There is no true market for small cap biotech, for if there was, AVXL would be north of $15 today.
Wouldn't be surprised if it closes at 5.24 again. Orchestrated manipulation! But would be a double bottom at that...which could be a signal to go long.
Can we get to 200k shares today? Zzzz
F1ash, on second look, the 11% includes Skarpelos's and Missling's 2.3M shares. Obviously, they are not institutions.
Also, can you explain the differences in the share amounts between Institutional Holders and Mutual Fund Holders, for example Vanguard's holdings? Their Institutional holdings is only 460.8k shares, while their Mutual Fund holdings total 987.9k.
TIA!
You are SPOT ON!
Thanks for the link, F1ash! Question: which number indicates insty ownership, the 5% or 11%? I presume 11%?
If we can close above 5.25, preferably above 5.30, it should indicate that the selling is over.
True, but with news (12/26-wk data, partnership, etc.) the game will be played at a higher PPS and with more and more retail buyers wanting in. So it won't be as easy for the MMs and hedgies to manipulate.
I'm anticipating fireworks in May! I feel pretty certain the 12-wk data is nearly ready. Or perhaps it's already available, but the 3rd-party company was told to hold onto it for a while (i.e. "Anavex doesn't have it")
I agree... this is setting up like November, but in the opposite direction: first walk it down, then shoot it up on good news.
Will do...
I'll be there...
Go right ahead; I don't have the time.
My replies to the GeoInvesting hit piece, which I'm sure won't get posted...
"This is the most blatant hit piece I've ever read...total hogwash!"
"The only fraud here is this website and the obvious attempts to manipulate information and the public from the facts! Referencing AF and MS is laughable. Somebody call the SEC!"
All of it is manufactured... that walk down, this walk down and perhaps some of the green shoots. At this MC, it is easily manipulated. Hopefully, they'll have less impact in the coming months when the PPS is north of $15.
I tried searching on GEOinvesting for "Anavex" and found nothing... ?
Noticed the below session at the myBIO conference...
Seems AVXL was an early adopter of the Adaptive Clinical Trial, which was guided by the FDA.
Revolutionizing Clinical Trials for Alzheimer’s: An International Perspective on Adaptive Clinical Trials
Dementia affects 47 million people globally, devastating lives and placing a huge burden on families, carers and society. Despite decades of research, there is still neither treatment nor cure for Alzheimer’s disease and success in clinical trials remains elusive. Pioneering projects on both sides of the Atlantic are working together to turn this situation around by running adaptive clinical trials – a first in Alzheimer’s research. In adaptive trials, multiple treatments are tested at the same time and the results analyzed continuously. This allows a faster assessment of treatments and the identification of groups of patients that respond best to them. In this session, leading dementia experts will share their experiences and trigger debate on how best to overcome the challenges to delivering successful clinical trials for much-needed Alzheimer’s treatments.
There's so much comfort in knowing what one owns!
The suspense is so high with me that I've decided to attend the shareholders' mtg to see what I can learn.
Thanks for laying that out... something to consider.
Capitulation? Strange how flat AVXL traded most of the day. It would SEEM we have established support for this week...drift up tomorrow with short covering and buying into the weekend?
Almost always, the support levels are pierced before moving higher. Why? Because just under are where most of the stop-loss orders sit.
I don't understand the logic in closing a gap that was artificially walked down to begin with. Perhaps someone could explain?
An abstract will be provided at the conference, according to the organizer's reply to a member's recent inquiry.
Seems they don't want to spoil the surprise!
Manipulators just ran the stops between 5.59 and 5.70
ODD was not "meaningless". It was good strategy to progress the approval of 3-71 in an advantageous way.